Tag Archives: nvs

Amgen, Novartis Alzheimer’s Deal Gets Cautious Praise

Big biotech Amgen (AMGN) was up in early trading Wednesday after it announced a neurology partnership with Novartis (NVS) as well as positive data on its osteoporosis drug candidate late Tuesday. Amgen and Novartis agreed to combine their research programs in Alzheimer’s disease, both of which involve drugs in the BACE (beta-site APP-cleaving enzyme-1) inhibitor class. BACE inhibitors, like the more advanced Alzheimer’s disease candidates from

Novartis’ Mixed Q2: Sandoz Booms, Alcon Struggles

Big Swiss pharma Novartis (NVS) early Tuesday reported a mixed Q2 and affirmed its guidance, and its shares fell. Novartis posted earnings of $1.27 a share, down 7% from the year-earlier quarter but up 7% on a constant-currency basis. That was 3 cents above analysts’ consensus, according to Thomson Reuters, though it missed both the Capital IQ and FactSet consensus estimates. Sales slid 5% to $12.7 billion, about $250 million above consensus. On a

Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer

Big pharma Bristol-Myers Squibb’s (BMY) new drug Opdivo scored another win Monday, as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. Small biotech Exelixis (EXEL) also reported success in a kidney-cancer trial, driving its embattled stock up 50%. Bristol-Myers’ trial, called Checkmate-025, compared Opdivo with everolimus, better known as Novartis’ (NVS) Afinitor, in patients with advanced or